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Aim: Chronic stable angina is the most prevalent symptom of ischaemic heart disease and its 
management is a priority. Current guidelines recommend pharmacological therapy with drugs 
classified as being first line (beta blockers, calcium channel blockers, short acting nitrates) 
or second line (long-acting nitrates, ivabradine, nicorandil, ranolazine, trimetazidine). 
Second line drugs are indicated for patients who have contraindications to first line agents, do 
not tolerate them or remain symptomatic. Evidence that one drug is superior to another has 
been questioned.  
Methods and Results : Between January and March 2018, we performed a systematic 
review of articles written in English over the past 50 years English-written articles in Medline 
and Embase following preferred reporting items and the Cochrane collaboration approach. 
We included double blind randomized studies comparing parallel groups on treatment of 
angina in patients with stable coronary artery disease, with a sample size of, at least, 100 
patients (50 patients per group), with a minimum follow-up of one week and an outcome 
measured on exercise testing, duration of exercise being the preferred outcome. Thirteen 
studies fulfilled our criteria. Nine studies involved between 100 and 300 patients, (2818 in 
total) and a further 4 enrolled greater than 300 patients. Evidence of equivalence was 
demonstrated for the use of beta-blockers (atenolol), calcium antagonists (amlodipine, 
nifedipine) and channel inhibitor (ivabradine) in 3 of these studies. Taken all together, in 
none of the studies was there evidence that one drug was superior to another in the treatment 
of angina or to prolong total exercise duration. 
Conclusion: There is a paucity of data comparing the efficacy of antianginal agents. The 
little available evidence shows that no antianginal drug is superior to another and equivalence 
has been shown only for three classes of drugs. Guidelines draw conclusions not from 





































































The first effective treatment for angina, amyl nitrate, was described in 1867 (1) and subsequently in 
1879 the benefits of nitroglycerine were reported (2). However it was not until 1964 that propranolol, 
the first clinically available beta blocker, was introduced into clinical practice for the long term oral 
management of chronic stable angina (3). Calcium antagonists were identified in 1964 (4) and in 1975 
became available (5), licenced for the treatment of angina. Around this time, long acting nitrates in the 
form of isosorbide dinitrate began to be used for chronic oral therapy (6); the earlier preparations of 
long-acting nitrates were hampered by the development of drug tolerance (7).  Subsequently, 
modulators of myocardial metabolism (Trimetazidine) (8), ATP-dependent potassium channel 
openers (Nicorandil) (9), If channel inhibitors (Ivabradine) (10) and late inward sodium channel 
inhibitors (Ranolazine) (11) were introduced. In the late 60s/ 70s, a better understanding of the 
pathophysiology of angina began to emerge and it became clear that all these various agents improved 
the symptoms of angina but by different mechanisms. 
  
According to the guidelines, drugs for the symptomatic relief of angina are classified as being first 
line (beta blockers, calcium channel blockers with short acting nitrates on request) or second line 
(long-acting nitrates, Nicorandil, Ivabradine, Trimetazidine and Ranolazine) with the recommendation 
to reserve second line medications for patients who have contraindications to first line agents, do not 
tolerate them or remain symptomatic (12). However, what is the evidence that any one of these 
treatments is superior to another? The purpose of this systematic review is to examine the evidence 
accumulated over the past 50 years since the introduction of propranolol for the efficacy of one anti-








































































We performed a systematic review of the literature following Preferred Reporting Items for 
systematic Reviews and Meta-analysis (PRISMA). Appropriate articles were searched in MEDLINE 
and in EMBASE. The search was carried out between January and March 2018 to include all papers 
published in English specifically for the treatment of angina in patients with a diagnosis of stable 
coronary artery disease and which fulfilled the following criteria: namely, double blind randomized 
clinical trials comparing parallel groups, two anti-anginal drugs, with a sample size of at least 100 
patients (50 patients per treatment group) and a follow-up lasting at least one week. Studies of less 
than 100 patients (<50 patients per group) were not considered since they were under-powered to 
draw any meaningful conclusion. Studies comparing an anti-anginal drug versus another drug within 
the same class were excluded. The inclusion of the papers in the systematic review was decided after 
analysis of the full-text of papers selected (Figure 1s – supplemental online material). 
 
The outcome of interest was related to the effect of the drugs on the primary outcome measured on 
exercise testing. Where a number of different exercise parameters were included in the primary 
outcome then the duration of exercise was selected as the primary outcome. 
The quality of the included studies was evaluated with the Cochrane Collaboration approach. In 
particular, the risk of analytical, selection, adjudication, and attrition bias (expressed as low, 
moderate, or high risk of bias, as well as incomplete reporting leading to inability to ascertain the 







































































We identified 72 controlled randomised trials comparing two anti-anginal drugs since 1964 which 
included 7034 patients (Figure 1). A total of 13 studies fulfilled the criteria set out (13-25), of which 9 
enrolled between 100 and 300 patients with more than  50 patients per group (Figure 2). The 
remaining 4 enrolled more than 300 patients (>150 patients per group) (Figure 3) (17;22;23;25). Table 
1 describes the 13 selected studies with the primary outcome results of beta blockers compared to 
other agents, calcium antagonists compared to other agents and long acting nitrates compared to other 
agents, respectively. 
  
In the 9 studies enrolling between 100 and 300 patients there was a total of 1611 patients evaluated 
(13-16;18-21;24). There was only one study where metoprolol was found to be superior to nifedipine 
on the primary end point (time to 1mm ST depression); however the total exercise time was not 
improved (15). Thus, in none of the studies was total exercise duration prolonged by any treatment 
compared to another.  
 
In the 4 studies enrolling more than 300 patients there was a total of 2818 patients evaluated. Again 
no evidence was found of one drug being superior to another (beta blockers, calcium antagonists and 
If channel inhibitors being tested) with evidence of equivalence between these agents established in 








































































This systematic review over the entire history of orally active treatments for the management of 
angina pectoris demonstrates that there is paucity of data. Guidelines draw conclusions not from what 
little data there is but from firmly held clinical beliefs. This is of particular concern bearing in mind 
that chronic stable angina is one of the most important causes of morbidity worldwide and drugs for 
the treatment of angina are among the most prescribed of any treatment today. On the basis of this 
systematic review we can conclude no one anti-anginal drug is superior to another and equivalence 
has only been demonstrated for the use of beta blockers (atenolol), calcium antagonists (amlodipine, 
nifedipine) and If channel inhibitors (ivabradine). 
 
Although the entry criteria for our analysis was a minimum of 100 patients (at least 50 patients per 
group in double blind parallel group studies) we did review the literature for any crossover studies 
with at least 100 patients. Only one compared atenolol with ranolazine and there was no difference in 
the primary endpoint of time to angina onset; this was following one week of treatment without a 
washout phase in between the crossover (26). 
 
  
The development of orally active anti-anginal agents has moved in parallel with the development of 
clinical trials to test these agents. Clinical trials in the early days were naive in their concept with no 
understanding of power calculations, hazard ratios etc. or even awareness that failure to prove 
superiority does not imply equivalence. Other issues in the earlier studies have made difficult the 
comparison with the those conducted more recently, for example studies with calcium antagonists 
evaluated the effect of stress test at peak plasma levels, whereas it is currently asked to show benefit 
at trough level of the drugs which actually is available only for ivabradine and ranolazine. In an 
attempt to try and draw sound conclusions to confirm if any one drug is superior to another in the 
management of angina we have chosen to limit our analysis to those studies with at least 50 patients 




































































different methodologies and in particular different somewhat immature methods of analysis make it 
impossible to perform a formal meta analysis. On the other hand, failure to show superiority in any of 
the selected studies with at least 100 patients would provide good evidence that no one anti-anginal 
therapy is superior to another. In order to say that one anti-anginal is equivalent to another we have 
also concentrated on those studies with more than 150 patients per treatment arm, the likely minimum 
number to draw this conclusion. 
  
Several different methodologies have in the past been used to assess the success of an anti-anginal 
agent namely angina diaries, GTN consumption as well as different parameters of the exercise 
ECG.  Subjective assessment of angina frequency and GTN consumption is an unreliable efficacy tool 
since as patients improve they may do more exercise and not necessarily reduce their angina 
frequency or GTN consumption; today this would be better assessed with Quality of Life 
questionnaires. The exercise test using exercise duration or exercise time to moderate angina is 
considered the gold standard to test an anti-anginal agent by the European and American Agencies 
(27). In the earlier studies, where a single primary endpoint was not selected we have taken exercise 
duration as the primary assessment criterion. 
  
In the absence of superiority of any one anti-anginal agent over another and equivalence demonstrated 
between beta blockers, calcium antagonists, and If channel inhibitors, how do we proceed to select the 
best anti-anginal agent for individual patients?  
 
Studies used to test anti-anginal agents took no regard as to the underlying pathophysiology of the 
angina symptoms when selecting patients for investigation. It has become clear there are different 
mechanisms responsible for ischaemia some of which may predominate more in one patient than 
another. In any patient with angina, increased myocardial oxygen demand, reduction in coronary 
blood flow (including as a result of epicardial vasospasm or coronary microvascular dysfunction) 
with alterations in left ventricular filling pressure (that may affect both coronary flow and myocardial 




































































recent improved understanding of microvascular angina and the circumstances where it may occur 
(e.g. post angioplasty angina) has added a whole new dimension as to the appropriate treatment of 
angina.Various classes of drugs work in different ways, for example beta blockade effectively reduces 
myocardial oxygen demand but at the expense in certain instances of an increase in coronary vascular 
resistance; consequently, patients with Prinzmetal angina or microvascular spasm may actually 
deteriorate by treatment with a beta blocker but benefit from treatment with a vasodilator such as a 
calcium antagonist. In addition, the primary choice of antianginal drug should also take in 
consideration common comorbidities such as hypertension, mitral regurgitation, atrial fibrillation, 
autonomic dysfunction and so forth. It is therefore plausible to consider to select our first line 
treatment of angina according to our understanding of the predominant pathophysiological 
mechanisms operating in each individual patient and his or her comorbidities. Similarly, add on 
therapy is likely to be more effective when considering the potential mechanisms of action. 
  
Also, co-morbidities will be important in selecting the appropriate treatment; for example, in those 
patients with heart failure a beta blocker and/or Ivabradine should be preferred, patients with diabetes 
may do better with a calcium antagonist which may also provide more effective blood pressure 
control. Co-morbidities that are contraindications to use a particular class of drugs will clearly define 
the appropriate treatments. Anti-anginal drugs without hemodynamic effects might be preferred in 
patients with low heart rate or low blood pressure. 
  
In conclusion, treatment of chronic angina with the so called first line choice is based upon drugs 
approved many years ago, with criteria that nowadays would be insufficient. There is no evidence to 
support the use of first and second line treatments for the management of angina. Rather, the medical 
therapy of angina should be personalized and tailored towards the individual with an understanding of 
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Table 1. Trials directly comparing beta-blockers, calcium antagonists, long-acting 
nitrates, nicorandil, trimetazidine, and ivabradine for stable angina.  
Author Medication 





At trough or peak activity  
Results for PEP 
 
Beta-Blockers vs other   
VAN DER DOES R. 
(1992)(13) 








At trough (12 h after last intake) 
TED at W4 (W x min): NS  
350  ± 195 to 471 ± 226 (CARV)  
387  ± 286 to 471 ± 261 (NIF) 
ARDISSINO D. (1995) 
(15) 







At peak (1h and 4h after last intake) 
PEP: TST <1mm at W6: S 
TST: 68 s (MET) vs 42 s (NIF), p<0.05 in favour of 
MET 
TED: 44 s(MET) vs 33 s (NIF), NS 
DETRY J.M.R. (1995) 
(16) 







At peak (3-4h after last intake) 
PEP: number of AA, TED, TST >1mm at D90: NS 
AA: -3.5 (TMZ) vs -5.5 (Prop),  P =0.117 
TED (s): 33 (TMZ) vs 33 (Prop), p=0.982,  
TST (s): 50 (TMZ) vs 64 (Prop),  p=0.481 




SR 20mg bid 
1 year 
At peak (2-6h after last intake) 
TED at W6: NS 
91.4 (10) s (ATEN) vs 90.5 (11.1) (NIF) (treadmill)  
63.2 (11) (ATEN) vs 63.6 (13.3) (NIF) (bicycle) 
HAUF-ZACHARIOU U. 
(1997) (18) 







At trough (prior to the morning medication)  
PEP: TED at W12: NS 
380 (9) to 436 (11) (Carved) vs 386 (9) to 438 (11) 
(VER), P=0.6841   
PEHRSSON S.K. (2000) 
(20) 







At peak (2-3h after intake) 
PEP: TST >1mm (NS) by Week 10: NS 
1 min (AML) vs 0.8 (ATEN) 
TARDIF J.C. (2005) (22) Ivabradine vs BB 
632 (IVA)/ 
307 (ATEN) 




At trough (12h after last intake)  
PEP: TED at M4 (s): NS 
Change: +86.8±129.0 (IVA) vs. +78.8±133.4 s (ATEN).  
P< 0.001 for non-inferiority 
LI Y. (2014) (25) Ivabradine VS BB 
166 (IVA)/ 
166 (ATEN) 
5 or 7.5mg bid/ 
12.5 or 25mg bid 
12 
weeks 
At trough (before morning intake) 
PEP: TED at W12: NS 
Change: +84.1 ± 130.5 s (IVA) vs 77.8 ± 126.6 s 
(ATEN), p = 0.0011 for noninferiority 
       
 
Calcium Antagonist vs other  
GUERMONPREZ 









At peak (nicorandil was given at 8h and 20h, TET was 
done at 10h) 
Work to peak exercise by D90: NS 
42.3 ± 19 to 49.2 ±24.4 kJ (NIC)  
From 37.3  ± 18.6 to 46.8 ± 20.6 kJ (DILT), P=0.44 
CHATTERJEE T. 
(1999) (19) 







At trough (12-24 h after last intake) 
TED , W8 (min): NS 
6.7  ± 0.3 to 7.2 ± 0.3 (NIC)  











No information if it was at peak or at trough  
PEP: TED at D28 (NS) 
443.8  ± 117.1 to 477.5 ± 196.7 sec (TMZ)  
476.1  ± 187.5 to 493.5 ± 189.3 sec (DILT)  
RUZYLLO W. (2007) 
(23) 
Ivabradine vs CCB 
791 (IVA)/ 
404 (AML) 




At trough (12 h after last intake) 
PEP: TED at M3 (NS) 
Change: 27.6 ±91.7 (IVA) vs 31.2± 92.0 s (AML), p-
value for non-inferiority < 0.001 
 
Long Acting Nitrates vs other 







At peak (30 min and 2h after intake) 
PEP: TST <1mm by W2: NS  
Change: 59.7 ± 128.6 (NIC) vs 67.7 ±119.1, P=0.623 
 
 
BB: beta blocker: CCB: dihydropyridine calcium channel blockers; LAN: long acting nitrates; TMZ: trimetazidine; IVA: ivabradine; PEP: 
primary endpoint; TED: total exercise duration; MET: metabolic equivalent; W: week; CARV:  carvedilol; NIF: nifedipine; Prop: 
propranolol; NIC: nicorandil; ISMN: isosorbide mononitrates; ATEN: atenolol; DILT:diltiazem; MET: metoprolol; VER:verapamil; AML: 







































































Figure 1: RCT directly comparing beta-blockers, calcium antagonists, long-acting 
nitrates, nicorandil, trimetazidine, and ivabradine for stable angina (76 RCTs, n=7034 
patients). 
 
Figure 2: RCT directly comparing beta-blockers, calcium antagonists, long-acting 
nitrates, nicorandil, trimetazidine, and ivabradine for stable angina including 100-300 
patients (9 RCTs, n=1611 patients) 
 
Figure 3: RCT directly comparing beta-blockers, calcium antagonists, long-acting 
nitrates, nicorandil, trimetazidine, and ivabradine for stable angina including >300 
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Search strategy details for Pubmed 
(((("Angina, Stable"[Mesh] OR "Coronary Artery Disease"[Mesh]) NOT ("Angina, Unstable"[Mesh]AND "Acute 
Coronary Syndrome"[Mesh])))  
AND  
("Diltiazem"[Mesh] OR "Verapamil"[Mesh] OR "Bepridil"[Mesh] OR "Nifedipine"[Mesh] OR "Amlodipine"[Mesh] 
OR "Felodipine"[Mesh] OR "Isradipine"[Mesh] OR "lacidipine" [Supplementary concept]"Nicardipine"[Mesh] OR 
"Nitrendipine"[Mesh] OR "Nimodipine"[Mesh] OR "lacidipine" [Supplementary Concept] OR "Isosorbide 
Dinitrate"[Mesh] OR "isosorbide-5-mononitrate" [Supplementary Concept] OR "Molsidomine"[Mesh] OR 
"Nicorandil"[Mesh] OR "Ranolazine"[Mesh] OR "fasudil" [Supplementary Concept] OR "Gallopamil"[Mesh] OR 
"Trapidil"[Mesh] OR "Trimetazidine"[Mesh] OR "Acebutolol"[Mesh] OR "Atenolol"[Mesh] OR "Betaxolol"[Mesh] 
OR "Bisoprolol"[Mesh] OR "Celiprolol"[Mesh] OR "Metoprolol"[Mesh] OR "Nadolol"[Mesh] OR 
"Oxprenolol"[Mesh] OR "Pindolol"[Mesh] OR "Propranolol"[Mesh] OR "Timolol"[Mesh] OR "bopindolol" 
[Supplementary Concept] OR "Carteolol"[Mesh] OR "carvedilol" [Supplementary Concept] OR "Penbutolol"[Mesh] 
OR "Nebivolol"[Mesh] OR "Labetalol"[Mesh] OR "Sotalol"[Mesh] OR "ivabradine" [Supplementary Concept]))  
AND  





Search strategy details for EMBASE 
MJEMB.EXACT("stable angina pectoris") OR MJEMB.EXACT ("coronary artery disease") NOT MJEMB.EXACT 
("unstable angina pectoris") NOT MJEMB.EXACT("acute coronary syndrome")  
AND  
EMB.EXACT("nifedipine") OR EMB.EXACT("verapamil") OR EMB.EXACT("nicardipine") OR 
EMB.EXACT("bepridil") OR EMB.EXACT("lacidipine") OR EMB.EXACT("felodipine") OR 
EMB.EXACT("diltiazem") OR EMB.EXACT("amlodipine") OR EMB.EXACT("isradipine") OR 
EMB.EXACT("nitrendipine") OR EMB.EXACT("lacidipine") OR EMB.EXACT("isosorbide mononitrate") OR 
EMB.EXACT("nimodipine") OR EMB.EXACT("isosorbide dinitrate") OR EMB.EXACT("ranolazine") OR 
EMB.EXACT("molsidomine") OR EMB.EXACT("trapidil") OR EMB.EXACT("nicorandil") OR 
EMB.EXACT("fasudil") OR EMB.EXACT("betaxolol") OR EMB.EXACT("acebutolol") OR 
EMB.EXACT("gallopamil") OR EMB.EXACT("atenolol") OR EMB.EXACT("trimetazidine") OR 
EMB.EXACT("nebivolol") OR EMB.EXACT("celiprolol") OR EMB.EXACT("penbutolol") OR 
EMB.EXACT("propranolol derivative") OR EMB.EXACT("labetalol") OR EMB.EXACT("sotalol") OR 
EMB.EXACT("timolol") OR EMB.EXACT("bopindolol") OR EMB.EXACT("metoprolol") OR 
EMB.EXACT("pindolol") OR EMB.EXACT("ivabradine") OR EMB.EXACT("carteolol") OR 
EMB.EXACT("bisoprolol") OR EMB.EXACT("nadolol") OR EMB.EXACT("oxprenolol") OR 
EMB.EXACT("carvedilol")  
AND 





Table 1s. Trials directly comparing beta-blockers, calcium antagonists, long acting nitrates, nicorandil, 
trimetazidine, ranolazine and ivabradine for stable angina 
 
Study selection: 
Randomized studies comparing directly antianginal drugs from 2 or 3 different classes in patients with stable angina, 
with duration at least 1 week and reporting at least 1 of the following outcomes: angina frequency, use of short acting 
nitrates, exercise test parameters.  
 




1969 BATTOCK D.J.1 BB vs LAN 12 Cross-over 
1969 GOLDBARG A.N. 2 BB vs LAN 21 Cross-over 
1970 AUBERT A. 3 BB vs LAN 21 Cross-over 
1973 LIVESLEY B. 4 BB vs Verapamil vs LAN 32 Parallel 
1980 LYNCH P. 5 BB vs CCB 16 Parallel 
1981 BOWLES M.J. 6 BB vs Verapamil 21 Cross-over 
1981 JOHNSON S.M.7 BB vs Verapamil 18 Parallel 
1982 ARNMAN K. 8 BB vs Verapamil 20 Cross-over 
1982 FRISHMAN W.H. 9 BB vs Verapamil 12 Cross-over 
1982 SADICK N.N. 10 BB vs Verapamil 18 Latin square 
1982 SOUTHALL E. 11 BB vs Verapamil 19 Cross-over 
1982 SUBRAMANIAN V.B. 12 BB vs Verapamil 22 Cross-over 
1983 BOWLES M.J. 13 BB vs Verapamil 21 Cross-over 
1983 FINDLAY I.N. 14 BB vs CCB 14 Latin square 
1983 HUNG J. 15 BB vs Diltiazem 12 Parallel 
1985 KENNY J. 16 BB vs Diltiazem 15 Cross-over 
1985 LIANG C.S. 17 CCB vs LAN 34 Parallel 
1985 RAE A.P. 18 BB vs CCB 35 Parallel 
1985 WHEATLEY D. 19 BB vs Diltiazem 78 Parallel 
1986 BJERLE P. 20 BB vs CCB 18 Cross-over 
1986 FINDLAY I.N. 21 BB vs CCB 16 Latin square 
1986 LOGAN R.L. 22 BB vs CCB 50 Cross-over 
1986 McGILL D. 23 BB vs CCB 25 Cross-over 
1986 PARKER J.O. 24 BB vs CCB 18 Cross-over 
1986 ROMANO M. 25 BB vs Diltiazem 13 Cross-over 
1987 DE DIVITIIS O. 26 BB vs Verapamil 26 Parallel 
1987 FINDLAY I.N. 27 BB vs Verapamil 15 Parallel 
1987 PFLUGFELDER P.W. 28 BB vs CCB 24 Cross-over 
1988 CRAKE T. 29 BB vs CCB 11 Cross-over 
1988 FRISHMAN W. 30 CCB vs Diltiazem 20 Cross-over 
1988 KLINKE W.P. 31 CCB vs Diltiazem 21 Cross-over 
1988 SCHNEIDER W. 32 LAN vs Verapamil 14 Cross-over 
1988 VAN DIJK R.B. 33 BB vs Diltiazem 33 Cross-over 
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1988 EMANUELSSON H. 34 LAN vs Diltiazem 25 Parallel 
1989 HIGGINBOTHAM M.B. 35 BB vs CCB 21 Cross-over 
1989 SHAPIRO W. 36 BB vs CCB 39 Parallel 
1990 DALLA-VOLTA S. 37 CCB vs Trimetazidine 39 Cross-over 
1990 HUGHES L.O. 38 BB vs Nicorandil 37 Parallel 
1990 STONE P.H. 39 BB vs Diltiazem vs CCB 63 Cross-over 
1991 BERNINK P.J.L.M. 40 CCB vs Diltiazem 39 Parallel 
1991 KREPP H.P. 42 BB vs LAN 30 Parallel 
1991 WAYSBORT J. 43 BB vs LAN 20 Parallel 
1992 FRISHMAN W.H. 44 BB vs CCB 75 Parallel 
1992 KAWANISHI D.T. 45 BB vs CCB 74 Parallel 
1992 LAI C. 46 BB vs CCB 16 Cross-over 
1992 MEETER K. 47 BB vs Nicorandil 71 Parallel 
1992 ULVENSTAM G. 48 CCB vs Nicorandil 58 Parallel 
1992 VAN DER DOES R. 49 BB vs CCB 166 Parallel 
1993 EGSTRUP K. 50 BB vs CCB 41 Parallel 
1993 GUERMONPREZ J.L. 51 Nicorandil vs Diltiazem 123 Parallel 
1993 PARAMESHWAR J. 52 BB vs CCB 30 Cross-over 
1993 RAFTERY E.B. 53 BB vs Nicorandil 31 Parallel 
1993 SINGH S. 54 BB vs CCB 80 Parallel 
1994 NADAZDIN A. 55 BB vs Diltiazem 15 Cross-over 
1994 WALLACE W.A. 56 BB vs CCB 17 Cross-over 
1995 ARDISSINO D. 57 BB vs CCB 280 Parallel 
1995 DETRY J.M.R. 58 BB vs Trimetazidine 149 Parallel 
1995 VAN DE VEN L.L.M. 59 BB vs LAN 22 Cross-over 
1996 DI SOMMA S. 60 BB vs CCB 20 Latin square 
1996 FOX K.M. 61 BB vs CCB 608 Parallel 
1996 HEUBLEIN B. 62 CCB vs LAN 91 Parallel 
1996 SAVONITTO S. 63 BB vs CCB 200 Parallel 
1997 HAUF-ZACHARIOU U. 64 BB vs Verapamil 313 Parallel 
1997 KLEIN G. 65 BB vs CCB 52 Cross-over 
1997 STEFFENSEN R. 66 CCB vs LAN 59 Cross-over 
1998 KNIGHT C.J. 67 CCB vs Diltiazem 97 Parallel 
1999 CHATTERJEE T. 68 CCB vs Nicorandil 121 Parallel 
2000 BASU S.K. 69 CCB vs Diltiazem 20 Cross-over 
2000 PEHRSSON S.K. 70 BB vs CCB 442 Parallel 
2001 HALL R. 71 CCB vs LAN 97 Parallel 
2004 KOYLAN N. 72 Trimetazidine vs Diltiazem 116 Parallel 
2005 ROUSSEAU M.F. 73 BB vs Ranolazine 158 Cross-over 
2005 TARDIF J.C. 74 Ivabradine vs BB 939 Parallel 
2007 RUZYLLO W. 75 Ivabradine vs CCB 1195 Parallel 
2007 ZHU W.L. 76 LAN vs Nicorandil 232 Parallel 
2014 LI Y. 77 Ivabradine VS BB 168 Parallel 
 
 
BB = Beta blockers 
CCBH = dihydropyridine calcium channel blockers 
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ABSTRACT  
Aim: Chronic stable angina is the most prevalent symptom of ischaemic heart disease and its 
management is a priority. Current guidelines recommend pharmacological therapy with drugs 
classified as being first line (beta blockers, calcium channel blockers, short acting nitrates) or 
second line (long-acting nitrates, ivabradine, nicorandil, ranolazine, trimetazidine). Second line 
drugs are indicated for patients who have contraindications to first line agents, do not tolerate them 
or remain symptomatic. Evidence that one drug is superior to another has been questioned.  
Methods and Results : Between January and March 2018, we performed a systematic review of 
articles written in English over the past 50 years English written articles in Medline and Embase 
following preferred reporting items and the Cochrane collaboration approach. We included double 
blind randomized studies comparing parallel groups on treatment of angina in patients with stable 
coronary artery disease, with a sample size of, at least, 100 patients (50 patients per group), with a 
minimum follow-up of one week and an outcome measured on exercise testing, duration of exercise 
being the preferred outcome. Thirteen studies fulfilled our criteria. Nine studies involved between 
100 and 300 patients, (2818 in total) and a further 4 enrolled greater than 300 patients. Evidence of 
equivalence was demonstrated for the use of beta-blockers (atenolol), calcium antagonists 
(amlodipine, nifedipine) and channel inhibitor (ivabradine) in 3 of these studies. Taken all together, 
in none of the studies was there evidence that one drug was superior to another in the treatment of 
angina or to prolong total exercise duration. 
Conclusion: there is a paucity of data comparing the efficacy of antianginal agents. The little 
available evidence shows that no antianginal drug is superior to another and equivalence has been 
shown only for three classes of drugs. Guidelines draw conclusions not from evidence but from 
clinical beliefs.  
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